Author + information
- Anselm K. Gitta,b,
- Dominik Lautscha,b,
- Martin Horacka,b,
- Kian Keong Poha,b,
- Philippe Brudia,b,
- Larry Liua,b,
- Gaetano De Ferraria,b and
- Jean Ferrièresa,b
Background: The objective of the second Dyslipidemia International Study (DYSIS II) was to document LDL-C goal attainment among patients with documented coronary heart disease (CHD) or acute coronary syndrome (ACS).
Methods: The CHD cohort of DYSIS II included patients from 17 countries of Asia, Europe, and the Middle East aged ≥18 and with a complete fasting lipid profile. Patients were classified as treated (on lipid-lowering therapy [LLT] for ≥3 months) or untreated (not on LLT). We assessed LDL-C goal (<70 mg/dL) attainment and the kind and dose of LLTs in treated patients. Multivariable logistic regression was performed to identify variables predictive of LDL-C target attainment.
Results: We enrolled 6,794 patients with CHD, 6,370 (93.8%) were on LLT. Mean LDL-C values were significantly different between treated and untreated patients (86 mg/dL versus 117 mg/dL; P<0.001). The LDL-C target was attained by 30.6% of treated patients. Statin monotherapy was the most commonly used LLT (82.3% of patients), with atorvastatin the most frequently used statin (52.5% of statin users). The mean atorvastatin dose equivalent was 25 ± 18 mg/day. The atorvastatin dose equivalent was predictive of slightly higher odds of LDL-C goal attainment (OR 1.010, 95% CI 1.007-1.013). Diabetes was a strong predictor of goal attainment (OR 1.70, 95% CI 1.51-1.92).
Conclusions: In the CHD cohort of DYSIS II, rates of LDL-C goal attainment were low. The findings suggest that use of more potent LLTs may increase LDL-C attainment rates.
Poster Hall, Hall C
Friday, March 17, 2017, 10:00 a.m.-10:45 a.m.
Session Title: Advances in Cholesterol Measurement and Management
Abstract Category: 32. Prevention: Clinical
Presentation Number: 1106-046
- 2017 American College of Cardiology Foundation